Nonalcoholic fatty liver disease (NAFLD) silently affects approximately 80 to 100 million Americans, making it one of the most prevalent liver conditions in the United States. The troubling aspect of this disease is its stealthy nature: most people have no symptoms until significant liver damage has occurred. Fatty liver lab tests represent the most effective way to detect this condition early, when lifestyle changes can still prevent progression to more serious complications like cirrhosis or liver failure. Understanding which tests to order and how to interpret results empowers individuals to take control of their liver health before irreversible damage occurs.
Understanding Fatty Liver Disease and Why Testing Matters
Nonalcoholic fatty liver disease develops when excess fat accumulates in liver cells without alcohol consumption as the primary cause. This fat buildup triggers inflammation and cellular damage over time. The condition exists on a spectrum, starting with simple fatty liver (steatosis) and potentially advancing to nonalcoholic steatohepatitis (NASH), fibrosis, and eventually cirrhosis.
The challenge with NAFLD lies in its silent progression. Most individuals experience no noticeable symptoms during the early stages when intervention is most effective. By the time symptoms like fatigue, abdominal discomfort, or jaundice appear, substantial liver damage may have already occurred.
Risk Factors That Warrant Screening
Several conditions and lifestyle factors significantly increase your risk of developing fatty liver disease:
- Type 2 diabetes or prediabetes
- Obesity or being overweight, particularly with abdominal fat distribution
- Insulin resistance and metabolic syndrome
- High cholesterol or triglyceride levels
- High blood pressure
- Polycystic ovary syndrome (PCOS)
- Sleep apnea
- Hypothyroidism
- Age over 50 years
Individuals with multiple risk factors should strongly consider regular fatty liver lab tests even without symptoms. The National Institute of Diabetes and Digestive and Kidney Diseases outlines the diagnostic process for NAFLD, emphasizing early detection through routine screening.

Essential Blood Tests for Fatty Liver Detection
Fatty liver lab tests typically begin with a comprehensive blood panel that evaluates liver function and metabolic health. These tests measure specific enzymes and substances that indicate liver damage or dysfunction.
Liver Function Tests (LFTs)
The most common starting point involves a liver function panel that measures several key enzymes:
| Test Name | Normal Range | What It Indicates |
|---|---|---|
| ALT (Alanine Aminotransferase) | Men 9-46 U/L; women 6-29 U/L | Liver cell damage; elevated in NAFLD |
| AST (Aspartate Aminotransferase) | 10-40 U/L | Liver inflammation; less specific than ALT |
| ALP (Alkaline Phosphatase) | 44-147 U/L | Bile duct function; may elevate with liver disease |
| Bilirubin (Total) | 0.1-1.2 mg/dL | Liver processing ability; elevated indicates dysfunction |
| Albumin | 3.5-5.5 g/dL | Liver synthetic function; decreased in advanced disease |
| GGT (Gamma-Glutamyl Transferase) | 9-48 U/L | Sensitive marker for alcohol-related liver damage and bile duct problems |
ALT and AST are particularly significant in fatty liver disease. Research on liver function tests and metabolic-associated fatty liver disease demonstrates that even values within the upper normal range may indicate early disease. The AST/ALT ratio also provides diagnostic clues: a ratio less than 1 typically suggests NAFLD, while a ratio greater than 2 may indicate alcoholic liver disease or cirrhosis. Over time, advancing fibrosis often pushes the ratio above 1.0, which is one reason the AST/ALT ratio is worth following. Your clinician may also check INR, which reflects clotting factors made by the liver; an elevated INR suggests impaired liver function.
Recommended Test
Hepatic Function Panel
A comprehensive 7-biomarker panel that evaluates liver health by measuring enzymes, proteins, and bilirubin levels.
Includes 7 biomarkers
$6.50
Metabolic Panel Tests
Since fatty liver disease closely links to metabolic dysfunction, comprehensive testing should include:
- Fasting glucose and hemoglobin A1C: These tests identify diabetes or prediabetes, major contributors to NAFLD. Getting an A1C test helps monitor long-term blood sugar control. A normal A1C is below 5.7%, and many patients see liver enzyme improvements simply by optimizing glucose control.
- Lipid panel: Measures total cholesterol, LDL, HDL, and triglycerides, which often show abnormalities in fatty liver patients. Triglycerides above 150 mg/dL directly promote liver fat accumulation, and low HDL (below 40 mg/dL in men, 50 mg/dL in women) indicates metabolic syndrome; the combination of high triglycerides and low HDL is linked to particularly aggressive fatty liver disease.
- Insulin levels: Fasting insulin tests can reveal insulin resistance before diabetes develops. The calculated HOMA-IR above 2.5 suggests significant resistance driving liver fat deposition.
Many individuals find that ordering lab tests without insurance provides a more affordable option for regular monitoring, especially when tracking multiple metabolic markers over time.
Recommended Panel
Fatty Liver Panel
Save $3.50Fatty liver disease, now called MASLD (formerly NAFLD), usually shows up first in routine blood work. This panel pairs a liver enzyme test with the metabolic markers that drive fatty liver, and includes every lab value your clinician needs to calculate a FIB-4 score, the first step guidelines use to judge whether the liver has started to scar.
Includes 40 biomarkers
$41.40
Fasting required
Advanced Diagnostic Tests for Fatty Liver Assessment
When initial fatty liver lab tests suggest liver dysfunction, more specialized testing helps determine disease severity and guide treatment decisions.
FIB-4 Index and NAFLD Fibrosis Score
These calculated scores use existing blood test results combined with age to estimate fibrosis risk:
FIB-4 Index Formula: (Age × AST) / (Platelet Count × √ALT)
- Score <1.30: Low risk of advanced fibrosis
- Score 1.30-2.67: Indeterminate risk, further testing needed
- Score >2.67: High risk of advanced fibrosis
According to EASL-EASD-EASO guidelines, FIB-4 serves as the preferred first-line screening tool because of its accessibility and validation across diverse populations. An indeterminate score is usually followed by a second-line test such as ELF or elastography, while a high score calls for specialist referral.
NAFLD Fibrosis Score incorporates age, BMI, platelet count, albumin, AST/ALT ratio, and presence of diabetes or impaired fasting glucose. It performs particularly well at excluding advanced fibrosis when values fall below -1.455. These non-invasive tools help identify patients who need more intensive evaluation without immediately requiring liver biopsy.
Enhanced Liver Fibrosis (ELF) Test
The ELF test measures three blood biomarkers that correlate with liver scarring:
- Hyaluronic acid (HA)
- Procollagen III amino-terminal peptide (PIIINP)
- Tissue inhibitor of metalloproteinase 1 (TIMP-1)
This specialized panel provides more detailed assessment of fibrosis progression than standard liver function tests alone. ELF scores above 9.8 suggest significant fibrosis warranting specialist evaluation, and the test works particularly well as a second-tier assessment when FIB-4 or the NAFLD Fibrosis Score falls in the indeterminate range. Comprehensive resources on fatty liver disease evaluation describe how laboratory studies complement imaging and clinical assessment.

Imaging Studies That Complement Laboratory Testing
While blood tests provide crucial information about liver function and metabolic health, imaging studies visualize fat accumulation and structural changes within the liver itself.
Ultrasound
Abdominal ultrasound represents the most common first-line imaging test for suspected fatty liver disease. This non-invasive, radiation-free procedure can detect moderate to severe fat accumulation (affecting more than 20-30% of liver tissue). However, ultrasound has limitations:
- Cannot reliably detect mild steatosis
- Cannot distinguish between simple fatty liver and NASH
- Operator-dependent accuracy
- Less effective in obese patients
FibroScan (Transient Elastography)
This specialized ultrasound technology measures liver stiffness, which correlates with fibrosis severity. FibroScan also quantifies fat content through controlled attenuation parameter (CAP) scoring. The test provides numerical results that help stage disease severity:
| Stiffness (kPa) | Fibrosis Stage |
|---|---|
| <7.0 | F0-F1 (Minimal) |
| 7.0-9.5 | F2 (Moderate) |
| 9.5-12.5 | F3 (Severe) |
| >12.5 | F4 (Cirrhosis) |
MRI-Based Assessments
Magnetic resonance imaging provides the most accurate non-invasive assessment of liver fat content and fibrosis. MRI-PDFF (proton density fat fraction) can detect even small amounts of liver fat, while MR elastography measures liver stiffness similarly to FibroScan but with greater accuracy. The primary drawback involves cost and availability.
When Liver Biopsy Becomes Necessary
Pathologic diagnosis of fatty liver disease sometimes requires direct tissue examination through liver biopsy, particularly when non-invasive tests yield inconclusive results or suggest advanced disease. A small tissue sample allows pathologists to:
- Definitively diagnose NASH versus simple steatosis
- Accurately stage fibrosis severity
- Identify concurrent liver conditions
- Guide treatment decisions for advanced cases
Biopsy is typically reserved for specific situations:
- Conflicting results between blood tests and imaging studies
- Suspected advanced fibrosis or cirrhosis
- Evaluation for clinical trial participation
- Ruling out other liver diseases
- Patients with multiple risk factors and abnormal test results
The procedure carries small risks including bleeding, infection, and pain, which is why physicians prefer non-invasive fatty liver lab tests for initial screening and monitoring.
Interpreting Your Test Results
Understanding what fatty liver lab tests reveal requires context beyond simply comparing numbers to reference ranges. Patterns across multiple tests provide more meaningful information than individual values in isolation.
Reading Your Liver Enzyme Results
Elevated ALT with normal or mildly elevated AST typically indicates NAFLD, especially when accompanied by metabolic risk factors. The degree of elevation correlates somewhat with disease severity, though many people with significant liver fat accumulation maintain relatively normal enzymes.
Questions on diagnosis and management of NAFLD address common concerns about interpreting lab values. Even persistently elevated enzymes within the upper normal range may warrant investigation in patients with risk factors.
Several factors can shift liver enzyme results independently of liver fat:
- Time of day: Enzyme levels fluctuate throughout the day
- Recent exercise: Intense physical activity raises AST levels
- Medications and supplements: Acetaminophen, statins, many antibiotics and some herbal supplements can elevate enzymes
- Body weight: Obesity independently affects enzyme levels
- Concurrent conditions: Muscle disorders, thyroid disease, and celiac disease impact results
Understanding Trends Over Time
A single set of abnormal results provides less information than tracking values over months or years. Progressive elevation of liver enzymes suggests worsening liver damage, while stable or improving values indicate successful lifestyle interventions or treatment.
Regular monitoring through affordable lab test pricing makes it feasible to track trends without the financial burden of insurance deductibles or copays for each test.

Testing Frequency Recommendations
How often you should repeat fatty liver lab tests depends on your initial results, risk factors, and whether you've made lifestyle changes.
For Initial Screening
Individuals with risk factors but no prior testing should establish a baseline with comprehensive metabolic and liver function panels. This initial assessment identifies whether further investigation is needed.
For Confirmed Fatty Liver
After diagnosis, testing frequency varies:
- Every 3-6 months: During active weight loss or lifestyle modification to monitor improvement
- Every 6-12 months: For stable disease without concerning features
- Every 3 months: When liver enzymes are significantly elevated or fibrosis markers suggest progression
Diagnostic evaluation of NAFLD emphasizes the importance of serial testing to detect disease progression early.
For Advanced Disease
Patients with confirmed fibrosis or cirrhosis require more intensive monitoring, potentially including quarterly liver function tests and biannual imaging studies to screen for complications including hepatocellular carcinoma.
Tracking Fatty Liver Over Time After a Diagnosis
Once fatty liver is confirmed, testing shifts from detection to direction: is the liver improving, stable, or scarring?
What to Trend Beyond ALT and AST
| Marker | What a worrying trend looks like |
|---|---|
| Platelet count | Progressive drops over 6-12 months may indicate worsening fibrosis, even when liver enzymes appear stable, as scarring advances and the spleen enlarges |
| Albumin | A decline over time suggests worsening liver function; most people with uncomplicated fatty liver keep normal albumin |
| Bilirubin | Rising bilirubin in someone with known fatty liver may signal progression toward decompensated cirrhosis |
| FIB-4 / NAFLD Fibrosis Score | A sustained climb; these scores fluctuate with age, weight, and transient factors, so focus on 12-month trends rather than 3-month variations |
For platelets, a normal range is 150,000-400,000/μL; 100,000-150,000/μL is a mild concern, and below 100,000/μL is a significant concern. Mean platelet volume (MPV) often rises as platelet count falls in chronic liver disease. The CBC with differential provides both.
Reading the Direction of Change
- Falling enzymes: Declining ALT and AST over 6-12 months indicates successful treatment response, even if values haven't reached the normal range.
- Climbing enzymes: Steadily rising values despite lifestyle changes warrant investigation for alternative causes or a discussion of medication with your doctor.
- Mixed signals: Improvements in HbA1c, triglycerides, and body weight should accompany falling liver enzymes. Improving glucose control with worsening liver inflammation might point to alcohol use, medication effects, or progressive disease.
- Normal enzymes: Normal ALT and AST indicate reduced inflammation but don't confirm that fat or scarring has cleared. The NHS overview of fatty liver disease explains that imaging or specialized biomarkers better assess actual fat content and fibrosis reversal, so keep monitoring.
A Step-by-Step Testing Pathway
Guidelines favor a tiered approach that balances accuracy and cost:
- Tier 1: Calculate FIB-4 or the NAFLD Fibrosis Score from routine blood work. Low risk: annual monitoring with basic panels. High risk: specialist referral. Indeterminate: move to Tier 2.
- Tier 2: An Enhanced Liver Fibrosis test or transient elastography. ELF below 9.8 suggests likely minimal fibrosis; ELF above 10.5 suggests likely advanced fibrosis and specialist management. Intermediate values may lead to a liver biopsy for definitive staging.
This approach, detailed in EASL clinical practice guidelines, minimizes unnecessary testing while ensuring high-risk patients receive appropriate evaluation.
Matching Tests to Your Treatment Phase
During active weight loss (targeting 7-10% body weight reduction), test on the 3-6 month schedule above to document changes in ALT, AST, triglycerides, and HbA1c. Liver enzymes often normalize after 6-12 months of sustained weight loss; recalculate fibrosis scores once you reach your target weight.
On medication therapy (such as vitamin E, pioglitazone, or GLP-1 agonists), get a baseline panel before starting, a follow-up at 3 months to assess response and side effects, and then continue monitoring every 3-6 months if you are responding.
During maintenance, once metabolic control is stable and enzymes have normalized, extend intervals to every 6-12 months, keep calculating a fibrosis score annually, and stay alert for recurrence if weight or metabolic control slips.
Keep a simple record of each test date, liver enzyme values (ALT, AST, ALP, GGT), metabolic markers (glucose, lipids, A1C), weight and BMI, and lifestyle or medication changes.
The Convenience of Direct-Access Testing
Traditional healthcare often creates barriers to regular monitoring. Insurance requirements, lengthy appointment scheduling, and high costs through insurance deductibles discourage people from getting the frequent testing needed to catch fatty liver disease early.
Self-pay lab testing removes these obstacles by allowing individuals to order tests online without a doctor's visit. This approach offers several advantages:
- Immediate access: Order tests when you're ready rather than waiting weeks for appointments
- Transparent pricing: Know the exact cost upfront without insurance complexity
- Quick results: Most results available within 1-3 days
- Convenient locations: Choose from thousands of patient service centers nationwide
- No insurance billing: Avoid deductibles, copays, and surprise bills
For individuals managing fatty liver disease through lifestyle changes, this accessibility enables more frequent monitoring to verify that interventions are working. Testing for NAFLD becomes more practical when logistical and financial barriers are removed.
Additional Tests to Consider
Beyond standard liver function panels, several complementary tests provide valuable context for fatty liver assessment.
Thyroid Function
Hypothyroidism contributes to metabolic dysfunction and fatty liver development. A thyroid panel measuring TSH, T3, and T4 helps identify this treatable condition.
Complete Blood Count (CBC)
A CBC measuring red blood cells, white blood cells, and platelets can reveal complications of advanced liver disease. Decreased platelet counts may indicate portal hypertension from cirrhosis.
Iron Studies
While rare, hereditary hemochromatosis (iron overload) can coexist with or mimic fatty liver disease. Ferritin, serum iron, and transferrin saturation tests screen for this genetic condition. Elevated ferritin occurs in about 30% of fatty liver patients, more often reflecting inflammation than true iron overload; full iron studies help distinguish the two, particularly when ferritin exceeds 300 ng/mL in men or 200 ng/mL in women. True iron overload accelerates fibrosis and needs specific management.
Uric Acid and Inflammation
- Uric acid: Elevated levels independently predict fatty liver development; values above 7 mg/dL in men or 6 mg/dL in women warrant attention alongside other metabolic abnormalities.
- hs-CRP: Values consistently above 3 mg/L indicate high cardiovascular risk and often correlate with more aggressive liver inflammation.
Autoimmune Markers
When standard fatty liver patterns don't fully explain abnormal liver tests, checking for autoimmune hepatitis through ANA (antinuclear antibody) and SMA (smooth muscle antibody) tests rules out concurrent conditions.
Recommended Test
GGT (Gamma-Glutamyl Transferase)
GGT is a liver enzyme that's particularly sensitive to alcohol use and bile duct problems. It's often elevated before other liver enzymes and can help determine the cause of elevated ALP (alkaline phosphatase).
Includes 1 biomarkers
$5
Making Sense of Complex Results
Understanding lab results can feel overwhelming when multiple values fall outside normal ranges. Several strategies help interpret complex fatty liver lab tests:
-
Focus on patterns: Multiple mildly abnormal values related to metabolic function often indicate NAFLD more reliably than a single markedly elevated enzyme.
-
Consider clinical context: Test results must be interpreted alongside symptoms, medical history, and physical examination findings.
-
Calculate risk scores: Use FIB-4 and NAFLD Fibrosis Score calculators to integrate multiple values into actionable risk assessments.
-
Track changes: Compare current results to previous tests to identify trends.
-
Consult healthcare providers: While direct-access testing provides autonomy, discussing results with a physician ensures appropriate follow-up.
Cost Considerations for Regular Monitoring
Managing fatty liver disease requires ongoing testing, potentially for years or decades. Cost becomes a significant factor in maintaining consistent monitoring.
Traditional healthcare billing creates unpredictable expenses. A "simple blood test" through insurance might cost $50 or $500 depending on deductible status, contracted rates, and billing practices. This uncertainty discourages regular testing.
Transparent self-pay pricing provides budget certainty. At JustLabs, a comprehensive metabolic panel is $8.50, a hepatic function panel $6.50 and a lipid panel $7.90, plus one $18 order fee per order, with no hidden fees or surprise bills. Many FSA and HSA accounts cover these tests, providing additional savings.
For someone monitoring fatty liver disease quarterly, annual testing costs might total roughly $140-200 through self-pay services such as JustLabs (a CMP and lipid panel each quarter is $35.50 per draw, including the $18 order fee) versus $1,000-3,000 through traditional insurance-based care (depending on deductible and copay structure).
Taking Action Based on Test Results
Fatty liver lab tests provide information, but results only matter if they prompt appropriate action. Different result patterns warrant different responses.
Normal Results with Risk Factors
If you have diabetes, obesity, or metabolic syndrome but normal liver enzymes and metabolic markers, continue lifestyle modifications and retest annually to catch early changes.
Mildly Elevated Enzymes
ALT values 1.5-2 times the upper limit of normal suggest early fatty liver disease. Focus on:
- Weight loss of 7-10% of body weight
- Regular physical activity (150+ minutes weekly), plus resistance training 2-3 days per week; exercise improves insulin sensitivity and liver fat even without significant weight loss
- A Mediterranean-style pattern: extra virgin olive oil, abundant vegetables, fruits and whole grains, moderate fish and poultry, limited red meat and processed foods
- Reduced refined carbohydrates and added sugars
- Improved sleep quality
- Retest in 3-6 months to assess improvement
Moderately to Severely Elevated Enzymes
Values more than twice the upper limit of normal require medical evaluation to rule out other liver conditions and assess disease severity. Imaging studies and possibly specialist referral become important next steps.
Evidence of Advanced Fibrosis
High FIB-4 scores or imaging suggesting cirrhosis warrant immediate gastroenterology or hepatology consultation for specialized management and complication screening.
Results or Symptoms That Need Prompt Medical Attention
Seek medical care promptly for ALT or AST above 10 times the upper limit of normal, jaundice (yellowing of skin or eyes), severe abdominal pain or swelling, unexplained weight loss or fatigue, dark urine or pale stools, or easy bruising or bleeding. Persistently elevated enzymes or no improvement despite lifestyle changes are also reasons to see your doctor.
Regular fatty liver lab tests represent your best defense against silent liver damage affecting tens of millions of Americans. Early detection through comprehensive blood work enables lifestyle interventions that can reverse fat accumulation and prevent progression to serious complications. Whether you're screening due to risk factors or monitoring known disease, convenient access to testing removes barriers to proactive health management. JustLabs makes regular liver health monitoring simple and affordable with transparent pricing, online ordering, and results delivered within days, empowering you to take control of your metabolic and liver health without navigating insurance complexity or waiting for appointments.
Related reading
References
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. PMID: 38851997. https://pubmed.ncbi.nlm.nih.gov/38851997/
Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH, LITMUS systematic review team(†). Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2020 Aug;73(2):252-262. doi: 10.1016/j.jhep.2020.03.036. PMID: 32275982. https://pubmed.ncbi.nlm.nih.gov/32275982/
Barros RK, Cotrim HP, Daltro CH, Oliveira YA. Hyperferritinemia in patients with nonalcoholic fatty liver disease. Rev Assoc Med Bras (1992). 2017 Mar;63(3):284-289. doi: 10.1590/1806-9282.63.03.284. PMID: 28489136. https://pubmed.ncbi.nlm.nih.gov/28489136/





